Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Paclitaxel/Carboplatin Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma.

NCT00111007 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00111007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00111007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Paclitaxel/Carboplatin Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma.
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2005
Completion date
January 31, 2009
Enrollment
270 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma